Loading company…
Chinese developer of innovative new molecular entity drugs for tumors, metabolic diseases, and infections.
Xuanzhu Biopharmaceutical Co., Ltd., established in 2002, designs and develops new molecular entity drugs in areas including anti-infection, cardiovascular and metabolic disease, and anti-tumor therapy. Its management team is made up mainly of doctors with more than 10 years of experience in drug design and clinical research. In 2018 the company obtained clinical approvals for several national class 1 new drugs, including XZP-3621, KBP-5081, and KBP-3571. Revenue comes from licensing drug candidates, strategic partnerships, and sales of its own therapeutics, along with milestone payments and royalties from co-development agreements.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in